Expert Review of Clinical Immunology最新文献_第10页

Molecular investigations on T cell subsets in patients affected by hypomorphic DCLRE1C mutation. 受低形 DCLRE1C 基因突变影响的患者体内 T 细胞亚群的分子研究。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-05-09 DOI: 10.1080/1744666X.2024.2352479

Mehmet Ali Karaselek, Tugce Duran, Serkan Kuccukturk, Esra Hazar, Oznur Dogar, Ayca Kıykım, Sukru Guner, Ismail Reisli, Sevgi Keles

{"title":"Molecular investigations on T cell subsets in patients affected by hypomorphic DCLRE1C mutation.","authors":"Mehmet Ali Karaselek, Tugce Duran, Serkan Kuccukturk, Esra Hazar, Oznur Dogar, Ayca Kıykım, Sukru Guner, Ismail Reisli, Sevgi Keles","doi":"10.1080/1744666X.2024.2352479","DOIUrl":"10.1080/1744666X.2024.2352479","url":null,"abstract":"Objective: In this study, we explored the expression of transcription factors, cytokines, and co-stimulatory molecules within the helper T (Th) cell subsets (Th1, Th2, Th17, and Treg) of patients with hypomorphic DCLRE1C gene mutations.Methods: The study comprised eight patients and five controls. Transcription factor and cytokine expressions of Th subsets and co-stimulatory molecules were investigated by qPCR and flow cytometric following T cell stimulation. The findings were compared between patients (non-HSCT) and with hematopoietic stem cell transplantation (HSCT).Results: Flow cytometric analyses; while the Treg rate was significantly lower in non-HSCT than in controls (p = 0.010), the IFN-γ rate was significantly higher in patients than in the control and HSCT groups (p = 0.016, p = 0.022, respectively). Co-stimulatory molecule expressions were significantly lower in non-HSCT than in control (p < 0.001), and there was a significant improvement after HSCT. Post-stimulation qPCR analysis, significant changes were detected in non-HSCT/control, non-HSCT/HSCT, and HSCT/control comparisons.Conclusions: Our study is the first study to molecularly investigate Th cell subsets in hypomorphic DCLRE1C patients. It was determined that abnormalities in Th cell subsets still persisted despite HSCT. There are still many conditions to be explained in these patients, and we believe that our study may shed light on future studies.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"393-399"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bullous pemphigoid and hypercoagulability: a review. 大疱性类天疱疮与高凝性：综述。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2025-01-08 DOI: 10.1080/1744666X.2025.2450766

Bingjie Zhang, Nan Yang, Li Li

{"title":"Bullous pemphigoid and hypercoagulability: a review.","authors":"Bingjie Zhang, Nan Yang, Li Li","doi":"10.1080/1744666X.2025.2450766","DOIUrl":"10.1080/1744666X.2025.2450766","url":null,"abstract":"Introduction: Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies against hemidesmosomal proteins in the basal membrane zone. The presence of a high incidence of thrombotic events has led to the identification of a hypercoagulable state in BP patients.Areas covered: This review highlights the interactions between coagulation and immune-inflammatory responses based on the currently available literature, as well as individual changes in characteristic coagulation parameters in BP. This review is based on publications up to August 2024 that were retrieved by a selective search in the PubMed database.Expert opinion: The hypercoagulable state and bullous pemphigoid (BP) have a reciprocally enhancing effect on each other. For clinicians, it is crucial to closely monitor the fluctuations in circulating coagulation markers among BP patients, such as D-dimer, fibrinogen, and fibrin degradation products (FDP). Furthermore, considering the interplay between coagulation and immune-inflammatory responses in BP, targeting the shared pathways in treatment strategies could be beneficial for patients who exhibit both BP and a hypercoagulable state.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"323-332"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum adipocytokines and inflammatory cytokines in pregnant women with gestational diabetes mellitus: clinical utility and development of a risk prediction model. 妊娠期糖尿病孕妇血清脂肪细胞因子和炎症细胞因子：临床应用及风险预测模型的建立

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-13 DOI: 10.1080/1744666X.2024.2438714

Kezhuo Liu, Huihui Wang

{"title":"Serum adipocytokines and inflammatory cytokines in pregnant women with gestational diabetes mellitus: clinical utility and development of a risk prediction model.","authors":"Kezhuo Liu, Huihui Wang","doi":"10.1080/1744666X.2024.2438714","DOIUrl":"10.1080/1744666X.2024.2438714","url":null,"abstract":"Background: This study analyzed the clinical utility of serum adipocytokines and inflammatory cytokines in gestational diabetes mellitus (GDM) and developed a quantitative nomogram prediction model.Research design & methods: General data were collected. Fasting venous blood was taken and levels of fasting plasma glucose (FPG), serum adipocytokines, and inflammatory cytokines were assessed. The main risk factors for GDM were analyzed by implementing univariate and multivariate logistic regression analysis. The weights of the main risk factors were assigned, and the nomogram prediction model for GDM was developed by R software. The efficacy of the nomogram model for GDM prediction was measured and analyzed by the receiver operating characteristic (ROC) curve and calibration curve.Results: The observation group possessed a higher proportion of family history of diabetes, raised FPG, LEP, Visfatin, hs-CRP, IL-6, and TNF-α contents, and lower ADP contents (all p < 0.05). Multivariate logistic regression analysis displayed that LEP, ADP, and IL-6 were the main risk factors for GDM (p < 0.05). Calibration curve was basically consistent with the original curve, suggesting good accuracy.Conclusion: Serum adipocytokines and inflammatory cytokines were the main risk factors for GDM. Developing a nomogram model can facilitate early diagnosis of GDM by physicians, allowing for timely interventions.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"369-375"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Future biomarkers for acute graft-versus-host disease: potential roles of nucleic acids, metabolites, and immune cell markers. 未来急性移植物抗宿主病的生物标志物：核酸、代谢物和免疫细胞标志物的潜在作用

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-18 DOI: 10.1080/1744666X.2024.2441246

Håkon Reikvam, Kimberley Hatfield, Miriam Sandnes, Øystein Bruserud

{"title":"Future biomarkers for acute graft-versus-host disease: potential roles of nucleic acids, metabolites, and immune cell markers.","authors":"Håkon Reikvam, Kimberley Hatfield, Miriam Sandnes, Øystein Bruserud","doi":"10.1080/1744666X.2024.2441246","DOIUrl":"10.1080/1744666X.2024.2441246","url":null,"abstract":"Introduction: Acute graft versus host disease (aGVHD) is a potentially lethal complication after allogeneic stem cell transplantation. Biomarkers are used to estimate the risk of aGVHD and evaluate response to treatment. The most widely used biomarkers are systemic levels of various protein mediators involved in immunoregulation or reflecting tissue damage. However, systemic levels of other molecular markers such as nucleic acids or metabolites, levels of immunocompetent cells or endothelial cell markers may also be useful biomarkers in aGVHD.Areas covered: This review is based on selected articles from the PubMed database. We review and discuss the scientific basis for further studies to evaluate nucleic acids, metabolites, circulating immunocompetent cell subsets or endothelial markers as biomarkers in aGVHD.Expert opinion: A wide range of interacting and communicating cells are involved in the complex pathogenesis of aGVHD. Both nucleic acids and metabolites function as soluble mediators involved in communication between various subsets of immunocompetent cells and between immunocompetent cells and other neighboring cells. Clinical and experimental studies suggest that both neutrophils, monocytes, and endothelial cells are involved in the early stages of aGVHD pathogenesis. In our opinion, the possible clinical use of these molecular and cellular biomarkers warrants further investigation.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"305-321"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of the recently approved drugs for treating atopic dermatitis in the context of their safety and efficacy: a systematic review and meta-analysis. 最近批准的治疗特应性皮炎药物的安全性和有效性评价：系统回顾和荟萃分析。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-18 DOI: 10.1080/1744666X.2024.2435657

Abdullah Alkattan, Abrar Alzaher, Dina Alhabib, Afnan Younis, Elham Alsalem, Nadia Suraj, Eman Alsalameen, Noura Alrasheed, Moneerah Almuhaidib, Mona H Ibrahim

{"title":"An evaluation of the recently approved drugs for treating atopic dermatitis in the context of their safety and efficacy: a systematic review and meta-analysis.","authors":"Abdullah Alkattan, Abrar Alzaher, Dina Alhabib, Afnan Younis, Elham Alsalem, Nadia Suraj, Eman Alsalameen, Noura Alrasheed, Moneerah Almuhaidib, Mona H Ibrahim","doi":"10.1080/1744666X.2024.2435657","DOIUrl":"10.1080/1744666X.2024.2435657","url":null,"abstract":"Introduction: The present paper aimed to conduct an updated systematic review and meta-analysis to evaluate the safety and efficacy of crisaborole, delgocitinib, and ruxolitinib in treating mild-to-moderate atopic dermatitis (AD).Methods: MEDLINE and Google Scholar databases were utilized to search articles published during the years 2015-2024. The review was limited to randomized controlled studies that measured specific outcomes for safety and efficacy aspects, including adverse events (AEs) or treatment-emergent adverse events (TEAEs) to evaluate safety and Investigator's static global assessment (ISGA) or improvement of at least 75% of Eczema Area and Severity Index (EASI-75) to evaluate efficacy.Results: The review included 17 articles in the analysis. The safety odds ratios (ORs) among participants using crisaborole, delgocitinib, and ruxolitinib were 1.14, 95% CI [0.97-1.36], 1.18, 95% CI [0.84-1.67], and 0.72, 95% CI [0.55-0.94], respectively, when compared to control groups. The three studied topical AD treatments were found to be significantly more effective compared to control groups (crisaborole, OR = 1.78, 95% CI [1.51-2.10], delgocitinib, OR = 6.34, 95% CI [3.57-11.27], and ruxolitinib, OR = 7.30, 95% CI [5.10-10.44]).Conclusion: Delgocitinib and ruxolitinib demonstrated favorable safety and effectiveness profiles across various age cohorts, whereas crisaborole raised concerns over its safety and efficacy, particularly in children.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"347-357"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interstitial lung disease in rheumatic diseases: an update of the 2018 review. 风湿性疾病中的肺间质疾病：2018年回顾的更新。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-02-01 Epub Date: 2024-09-24 DOI: 10.1080/1744666X.2024.2407536

Fabiola Atzeni, Alessandra Alciati, Francesco Gozza, Ignazio Francesco Masala, Cesare Siragusano, Nicolò Pipitone

{"title":"Interstitial lung disease in rheumatic diseases: an update of the 2018 review.","authors":"Fabiola Atzeni, Alessandra Alciati, Francesco Gozza, Ignazio Francesco Masala, Cesare Siragusano, Nicolò Pipitone","doi":"10.1080/1744666X.2024.2407536","DOIUrl":"10.1080/1744666X.2024.2407536","url":null,"abstract":"Introduction: Interstitial lung disease (ILD) is a potential severe complication of various rheumatic diseases, typically connective tissue diseases (CTD), associated with significant morbidity and mortality. ILD may occur during the course of the disease but may also be its first manifestation. Several cell types are involved in ILD's pathogenesis, and if not controlled, pulmonary inflammation may lead to pulmonary fibrosis.Areas covered: We searched PubMed, Medline, and the Cochrane Library for papers published between 1995 and February 2017 in the first version, and between 2017 and April 2023 using combinations of words. The most frequent systemic rheumatic diseases associated with ILD are systemic sclerosis (SSc), rheumatoid arthritis (RA), and idiopathic inflammatory myositis. Treatment and monitoring guidelines are still lacking, and current treatment strategies have been extrapolated from the literature on SSc and established treatments for non-pulmonary systemic rheumatic manifestations.Expert opinion: Given the complexity of diagnosis and the paucity of treatment trials, managing CTD patients with ILD is challenging. It requires the skills of multidisciplinary CTD-ILD clinics including at least rheumatologists and lung specialists.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"209-226"},"PeriodicalIF":3.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of anti-CD69 antibody therapy alone or in combination with anti-PD-1 in murine GBM. 在小鼠 GBM 中评估抗 CD69 抗体单独或与抗 PD-1 联合治疗的效果。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-02-01 Epub Date: 2024-10-14 DOI: 10.1080/1744666X.2024.2412770

Michal Nisnboym, Chaim T Sneiderman, Ambika P Jaswal, Zujian Xiong, Sarah R Vincze, ReidAnn E Sever, Han Zou, Stephen C Frederico, Sameer Agnihotri, Baoli Hu, Jan Drappatz, Ian F Pollack, Gary Kohanbash, Itay Raphael

{"title":"Assessment of anti-CD69 antibody therapy alone or in combination with anti-PD-1 in murine GBM.","authors":"Michal Nisnboym, Chaim T Sneiderman, Ambika P Jaswal, Zujian Xiong, Sarah R Vincze, ReidAnn E Sever, Han Zou, Stephen C Frederico, Sameer Agnihotri, Baoli Hu, Jan Drappatz, Ian F Pollack, Gary Kohanbash, Itay Raphael","doi":"10.1080/1744666X.2024.2412770","DOIUrl":"10.1080/1744666X.2024.2412770","url":null,"abstract":"Background: Glioblastoma (GBM) is an aggressive cancer with limited treatment options. Immunotherapy targeting CD69, an early activation marker on T cells, has shown promise in preclinical models of non-CNS malignancies. This study investigates anti-CD69 therapy alone or in combination with anti-PD-1 in a preclinical GBM model.Research design and methods: CD69 expression in GBM patient tissues was analyzed using the TCGA database. Therapeutic efficacy of anti-CD69 was tested in a murine GBM model with different regimens. Immune cell populations in the tumor microenvironment (TME) were assessed by flow cytometry.Results: Increased CD69 expression was observed in GBM patients compared to normal brain tissue and was associated with worse prognosis. Anti-CD69 treatment reduced percentages of CD69+ immune cells but did not improve survival in GBM-bearing mice. Increased PD-1 expression on NK cells was observed following anti-CD69 treatment. Anti-CD69 treatment was not improved by the addition of anti-PD-1 in vivo.Conclusions: This is the first study evaluating anti-CD69 therapy in a preclinical GBM model. Despite promising preclinical data in other cancers, anti-CD69 monotherapy or combination therapy with anti-PD-1 did not improve survival in this GBM model.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"239-247"},"PeriodicalIF":3.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nociplastic pain in axial spondyloarthritis and psoriatic arthritis: role of JAK kinases in immunopathology and therapeutic impact of JAK inhibitors. 轴性脊柱关节炎和银屑病关节炎中的非关节痛：JAK 激酶在免疫病理学中的作用以及 JAK 抑制剂的治疗效果。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-02-01 Epub Date: 2024-09-08 DOI: 10.1080/1744666X.2024.2400294

Natalya Horbal, Walter P Maksymowych

{"title":"Nociplastic pain in axial spondyloarthritis and psoriatic arthritis: role of JAK kinases in immunopathology and therapeutic impact of JAK inhibitors.","authors":"Natalya Horbal, Walter P Maksymowych","doi":"10.1080/1744666X.2024.2400294","DOIUrl":"10.1080/1744666X.2024.2400294","url":null,"abstract":"Introduction: Pain in both peripheral and axial joints is a major symptom in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Emerging evidence demonstrates pain mechanisms, beyond those related to inflammation or joint damage, based on aberrant processing of nociceptive stimuli peripherally as well as centrally. The Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling pathway has been implicated in the processing of pain beyond its role in mediating inflammation and inhibitors of this pathway approved for the treatment of axSpA and PsA have been shown to alleviate a broad array of pain outcomes in both axial and peripheral joints.Areas covered: We review recent definitions and standardization of the nomenclature for categorizing chronic pain according to causality, assessment tools to evaluate nociplastic pain, the pathophysiologic role of JAK-STAT signaling in nociplastic pain, evidence for the presence of nociplastic pain in axSpA and PsA, and the impact of JAK inhibitors (JAKi) on pain outcomes in clinical trials (PubMed: 01/01/2019-04/01-2024).Expert opinion: Nociplastic pain assessment has been confined almost entirely to the use of a limited number of questionnaires in cross-sectional studies of these diseases. Though effective for alleviating pain, it is unclear if JAKi specifically impact nociplastic pain.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"137-152"},"PeriodicalIF":3.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Conventional and new immunotherapies for immune system dysregulation in postpartum mood disorders: comparisons to immune system dysregulations in bipolar disorder, major depression, and postpartum autoimmune thyroid disease. 治疗产后情绪障碍免疫系统失调的传统和新型免疫疗法：与双相情感障碍、重度抑郁症和产后自身免疫性甲状腺疾病的免疫系统失调进行比较。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-02-01 Epub Date: 2024-10-29 DOI: 10.1080/1744666X.2024.2420053

Hemmo A Drexhage, Veerle Bergink, Sara Poletti, Francesco Benedetti, Lauren M Osborne

{"title":"Conventional and new immunotherapies for immune system dysregulation in postpartum mood disorders: comparisons to immune system dysregulations in bipolar disorder, major depression, and postpartum autoimmune thyroid disease.","authors":"Hemmo A Drexhage, Veerle Bergink, Sara Poletti, Francesco Benedetti, Lauren M Osborne","doi":"10.1080/1744666X.2024.2420053","DOIUrl":"10.1080/1744666X.2024.2420053","url":null,"abstract":"Introduction: Postpartum mood disorders are heterogenous disorders and comprise postpartum psychosis and postpartum depression. Evidence is accumulating that systemic monocyte/macrophage activation, low-grade inflammation and (premature senescence related) T cell defects increase the risk for mood disorders outside pregnancy by affecting the function of microglia and T cells in the emotional brain (the cortico-limbic system) leading to inadequate mood regulation upon stress.Areas covered: The evidence in the literature that similar immune dysregulations are present in postpartum mood disorders.Results: The physiological postpartum period is characterized by a rapid T cell surge and a mild activation of the monocyte/macrophage system. Postpartum mood disorder patients show a diminished T cell surge (including that of T regulatory cells) and an increase in low grade inflammation, that is, an increased inflammatory state of monocytes/macrophages and higher levels of serum pro-inflammatory cytokines.Expert opinion: Anti-inflammatory agents (e.g. COX-2 inhibitors) and T cell boosting agents (e.g. low-dose IL-2 therapy) should be further investigated as treatment. The hypothesis should be investigated that postpartum mood disorders are active episodes (triggered by changes in the postpartum immuno-endocrine milieu) in ongoing, dynamically fluctuating aberrant neuro-immune-endocrine trajectories leading to mood disorders in women (inheritably) vulnerable to these disorders.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"113-135"},"PeriodicalIF":3.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive value analysis of albumin-related inflammatory markers for short-term outcomes in patients with In-hospital cardiac arrest. 白蛋白相关炎症指标对院内心脏骤停患者短期预后的预测价值分析。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-02-01 Epub Date: 2024-09-04 DOI: 10.1080/1744666X.2024.2399700

Linlin Xiao, Feng Li, Yuanhui Sheng, Xueping Hou, Xixi Liao, Pengfei Zhou, Yuping Qin, Xiaoying Chen, Jinglun Liu, Yetao Luo, Dong Peng, Shan Xu, Dan Zhang

{"title":"Predictive value analysis of albumin-related inflammatory markers for short-term outcomes in patients with In-hospital cardiac arrest.","authors":"Linlin Xiao, Feng Li, Yuanhui Sheng, Xueping Hou, Xixi Liao, Pengfei Zhou, Yuping Qin, Xiaoying Chen, Jinglun Liu, Yetao Luo, Dong Peng, Shan Xu, Dan Zhang","doi":"10.1080/1744666X.2024.2399700","DOIUrl":"10.1080/1744666X.2024.2399700","url":null,"abstract":"Objective: This study investigated the predictive value of albumin-related inflammatory markers for short-term outcomes in in-hospital cardiac arrest (IHCA) patients.Methods: A linear mixed model investigated the dynamic changes of markers within 72 hours after return of spontaneous circulation (ROSC). Time-Dependent COX regression explored the predictive value. Mediation analysis quantified the association of markers with organ dysfunctions and adverse outcomes.Results: Prognostic Nutritional Index (PNI) and RDW-Albumin Ratio (RAR) slightly changed (p > 0.05). Procalcitonin-Albumin Ratio (PAR1) initially increased and then slowly decreased. Neutrophil-Albumin Ratio (NAR) and Platelet-Albumin Ratio (PAR2) decreased slightly during 24-48 hours (all p<0.05). PNI (HR = 1.646, 95%CI (1.033,2.623)), PAR1 (HR = 1.69, 95%CI (1.057,2.701)), RAR (HR = 1.752,95%CI (1.103,2.783)) and NAR (HR = 1.724,95%CI (1.078,2.759)) were independently associated with in-hospital mortality. PNI (PM = 45.64%, 95%CI (17.05%,87.02%)), RAR (PM = 45.07%,95%CI (14.59%,93.70%)) and NAR (PM = 46.23%,95%CI (14.59%,93.70%)) indirectly influenced in-hospital mortality by increasing SOFA (central) scores. PNI (PM = 21.75%, 95%CI(0.67%,67.75%)) may also indirectly influenced outcome by increasing SOFA (renal) scores (all p < 0.05).Conclusions: Within 72 hours after ROSC, albumin-related inflammatory markers (PNI, PAR1, RAR, and NAR) were identified as potential predictors of short-term prognosis in IHCA patients. They may mediate the adverse outcomes of patients by causing damages to the central nervous system and renal function.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"249-257"},"PeriodicalIF":3.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0